Drugmakers raise US prices on over 250 medicines
NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., including Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...
Over 250 medicines to cost more from January 1 in the U.S; is your critical drug in the list? Check here
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
Deccan Chronicle6d
Expiry of Rs 12k cr patented US drugs a big opportunity for pharma
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Pharmaceutical Technology7d
Ibrance by Pfizer for Rhabdomyosarcoma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Pharmaceutical Technology7d
Ibrance by Pfizer for Metastatic Brain Tumor: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase II drugs for Metastatic Brain Tumor have a 20% phase transition ...
Businessworld8d
slots bingo online
INR:9831. slots bingo online Results announced! Abbott made so much in three months AstraZeneca's COVID-19 vaccine is approved for emergency supply in the UK!
Businessworld8d
is there horse racing in ireland today
INR:1237. is there horse racing in ireland today Phase III clinical trial approval: new progress of Hengrui's blockbuster ...
Businessworld8d
horse racing around the world
Ganlai's FXR agonist ASC42 completes first patient dosing in US Phase I clinical trial Novartis' Kisqal is superior to Pfizer's Ibrance in metastatic breast cancer, with a median survival of 5 years N ...
precisionmedicineonline22d
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...
Hosted on MSN24d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival.
Yahoo Finance25d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
clinicaltrialsarena25d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...